Amgen (NASDAQ:AMGN) Price Target Cut to $291.00
Amgen (NASDAQ:AMGN – Free Report) had its price target cut by Morgan Stanley from $300.00 to $291.00 in a research note released on Wednesday morning, Benzinga reports. They currently have an equal weight rating on the medical research company’s stock. Several other research firms also recently weighed in on AMGN. Argus upped their price objective […]
More Stories
Analyzing Simulations Plus (NASDAQ:SLP) and Veea (NASDAQ:VEEA)
Veea (NASDAQ:VEEA – Get Free Report) and Simulations Plus (NASDAQ:SLP – Get Free Report) are both small-cap computer and technology...
Rugby Resources (CVE:RUG) Shares Down 25% – Time to Sell?
Rugby Resources Ltd. (CVE:RUG – Get Free Report) shares traded down 25% on Tuesday . The company traded as low...
Milos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) insider Milos Miljkovic sold 932 shares of the business’s stock in a...
Insider Selling: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells 4,028 Shares of Stock
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) CFO Blaine Davis sold 4,028 shares of the business’s stock in a...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 Shares
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in...
Bowen Acquisition Corp Adjourns Extraordinary Meeting to Discuss Extension Proposal
Bowen Acquisition Corp (NASDAQ:BOWNU) recently adjourned its extraordinary general meeting, initially scheduled for January 7, 2025. The purpose of the...